Evidence map›Paper›PMID 36647531›Full record

Article3 Biotech2023

Okan Onar, Pelin Telkoparan-Akillilar, Ozlem Yildirim

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in 3 Biotech, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Okan OnarDepartment of Biology, Faculty of Science, Ankara University, Ankara, Turkey.ORCID 0000-0003-4197-527X
Pelin Telkoparan-AkillilarDepartment of Medical Biology, Faculty of Medicine, Yuksek Ihtisas University, Ankara, Turkey.ORCID 0000-0003-0337-0763
Ozlem YildirimDepartment of Biology, Faculty of Science, Ankara University, Ankara, Turkey.ORCID 0000-0003-1018-0335
Ankara University · TRYüksek İhtisas Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although 5-fluorouracil (5-FU) is an important anticancer agent for the treatment of colorectal cancer, drug resistance, and dose-related side effects limit the effectiveness of the treatment. Therefore, developing new pharmaceuticals with effective and low toxicity is critically necessary for cancer therapy. This study aimed to investigate the cytotoxic activity of the

Indexed as

5-fluorouracilAnticancerCell-cycle arrestClitocybe nebularisColorectal carcinoma

Identifiers

PMID36647531
PMCPMC9839933
OpenAlexW4316037889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.